Cite
HARVARD Citation
Strati, P. et al. (2022). A phase 2, multicentre, open‐label trial (ACE‐LY‐003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma. British journal of haematology. pp. 76-85. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Strati, P. et al. (2022). A phase 2, multicentre, open‐label trial (ACE‐LY‐003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma. British journal of haematology. pp. 76-85. [Online].